title: Therapeutic Potentials of BDNF/TrkB in Breast Cancer; Current Status and Perspectives.
abstract: Brain-derived neurotrophic factor (BDNF) is a potent neurotrophic factor that has been shown to stimulate breast cancer cell growth and metastasis via tyrosine kinase receptors TrkA, TrkB, and the p75NTRdeath receptor. The aberrant activation of BDNF/TrkB pathways can modulate several signaling pathways, including Akt/PI3K, Jak/STAT, NF-kB, UPAR/UPA, Wnt/β-catenin, and VEGF pathways as well as the ER receptor. Several microRNAs have been identified that are involved in the modulation of BDNF/TrkB pathways. These include miR-206, miR-204, MiR-200a/c, MiR-210, MiR-134, and MiR-191; and these may be of value as prognostic and predictive biomarkers for detecting patients at high risk of developing breast cancer. It has been also been demonstrated that a high expression of genes involved in the BDNF pathway in breast cancer is associated with poor clinical outcome and reduced survival of patients. Several approaches have been developed for targeting this pathway, for example TKr inhibitors (AZD6918, CEP-701) and RNA interference. The aim of the current review was to provide an overview of the role of BDNF/TrkB pathways in the pathogenesis of breast cancer and its value as a potential therapeutic target. J. Cell. Biochem. 118: 2502-2515, 2017. © 2017 Wiley Periodicals, Inc.
authors.affiliation: Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.|Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
authors.forename: Amir
authors.initials: A
authors.lastname: Tajbakhsh
authors.affiliation: Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.|Neurogenic Inflammation Research Centre and Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
authors.forename: Amin
authors.initials: A
authors.lastname: Mokhtari-Zaer
authors.affiliation: Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.|Department of Medical Biotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
authors.forename: Mehdi
authors.initials: M
authors.lastname: Rezaee
authors.affiliation: Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.|Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
authors.forename: Fahimeh
authors.initials: F
authors.lastname: Afzaljavan
authors.affiliation: Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.|Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
authors.forename: Mehdi
authors.initials: M
authors.lastname: Rivandi
authors.affiliation: Department of Medical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.|Metabolic Syndrome Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
authors.forename: Seyed Mahdi
authors.identifier: 0000-0002-5247-4043
authors.initials: SM
authors.lastname: Hassanian
authors.affiliation: Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, UK.
authors.forename: Gordon A
authors.initials: GA
authors.lastname: Ferns
authors.affiliation: Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.|Division of Applied Medicine, Medical School, University of Aberdeen, Foresterhill, Aberdeen, UK.|Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
authors.forename: Alireza
authors.initials: A
authors.lastname: Pasdar
authors.affiliation: Metabolic Syndrome Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
authors.forename: Amir
authors.identifier: 0000-0002-4968-0962
authors.initials: A
authors.lastname: Avan
mesh_terms: D000818:Animals; D019208:Brain-Derived Neurotrophic Factor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D002227:Carbazoles / Q000627:therapeutic use; D005260:Female; D005663:Furans; D006801:Humans; D008562:Membrane Glycoproteins / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D035683:MicroRNAs / Q000378:metabolism; D009363:Neoplasm Proteins / Q000378:metabolism*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D034622:RNA Interference; D012334:RNA, Neoplasm / Q000378:metabolism; D020813:Receptor, trkB / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D060449:Wnt Signaling Pathway
chemical_list: D019208:Brain-Derived Neurotrophic Factor; D002227:Carbazoles; D005663:Furans; D008562:Membrane Glycoproteins; D035683:MicroRNAs; D009363:Neoplasm Proteins; D047428:Protein Kinase Inhibitors; D012334:RNA, Neoplasm; C579455:BDNF protein, human; C119379:lestaurtinib; D020813:Receptor, trkB; C000591259:tropomyosin-related kinase-B, human
keywords: BRAIN-DERIVED NEUROTROPHIC FACTOR; BREAST CANCER; EPIGENETICS; PHARMACOLOGICAL MODULATORS; RISK FACTOR